Part II: Targeted Particles for Imaging of Anticancer Immune Responses

Publisher： Bentham Science Publishers

E-ISSN： 1875-5704|8|3|274-281

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.8, Iss.3, 2011-05, pp. : 274-281

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Part I: Targeted Particles for Cancer Immunotherapy

By  

Current Drug Delivery, Vol. 8, Iss. 3, 2011-05 ,pp. : 261-273

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 3, 2013-03 ,pp. : 357-376

Bentham Science Publishers

Access to resources Recommend Favorite

Publication biases and phase II trials investigating anticancer targeted therapies

By Penel Nicolas   Adenis Antoine  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 287-288

Springer Publishing Company

Access to resources Recommend Favorite

Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response

By  

Current Medicinal Chemistry, Vol. 23, Iss. 41, 2016-12 ,pp. : 4625-4638

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [Hot topic: The Medicinal Chemistry of Targeted Tumor Imaging (II) (Guest Editor: Xiaoyuan (Shawn) Chen)]

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 12, 2010-08 ,pp. : 1145-1146

Bentham Science Publishers

Access to resources Recommend Favorite